奥赛康子公司签署ASKG712项目授权许可协议

Core Viewpoint - AskGene Pharma has entered into a licensing agreement with Visara for its innovative drug project ASK712, which targets both VEGF and ANG-2, indicating a strategic move towards enhancing its research and commercialization efforts in the therapeutic area of eye diseases [1][2] Group 1: Licensing Agreement - AskGene Pharma has licensed its proprietary rights for the innovative drug ASK712 to Visara, which is expected to facilitate the development and commercialization of the drug in the licensed area [1] - The licensing agreement aligns with the company's strategic focus on innovation in drug development, particularly in areas such as digestion, oncology, anti-infection, and chronic diseases [2] Group 2: Drug Development and Clinical Trials - ASK712 is currently in the Phase IIa clinical trial stage in China, demonstrating good safety and efficacy based on Phase I dose escalation and expansion results [1] - Preclinical data suggests that ASK712 has a stronger binding affinity for VEGF and ANG-2 compared to existing treatments, potentially improving efficacy and extending dosing intervals, which may enhance patient compliance [1]